Nasus Pharma Ltd filed a Form D with the Securities and Exchange Commission on 2026-02-25.
Nasus Pharma Ltd filed a Form D notice of an exempt securities offering with the SEC on February 25, 2026. The filing reports $15M sold. Its industry group is Biotechnology. It names Dan Teleman (Chief Executive Officer), Eyal Rubin (Chief Financial Officer and Executive Vice President), Udi Gilboa (Director) (SEC Form D, February 25, 2026).
Sell to companies like Nasus Pharma Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-02-25 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Nasus Pharma Ltd.
Free to see. No signup.
More on the people and the money behind Nasus Pharma Ltd, from the filings we hold.
Biotechnology raises by companies based in Israel, filed within 90 days of this one, largest first.
Get an email when Nasus Pharma Ltd files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Nasus Pharma Ltd raises, hires or launches. No email unless you switch it on.
Watch Nasus Pharma Ltd →Get the full cited report on Nasus Pharma Ltd
What the filing shows about Nasus Pharma Ltd
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Nasus Pharma Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Trailing twelve months. 766 filings in Biotechnology, totalled by week. The dot is this raise, $15M, on the same scale — one filing against the whole group's total, so it sits low by construction.
On the filing as: Executive Officer, Director.
Dan Teleman is named as Chief Executive Officer on the Form D that Nasus Pharma Ltd filed with the SEC on 25 February 2026, one of 8 people that filing names.
On the filing as: Executive Officer.
Eyal Rubin is named as Chief Financial Officer and Executive Vice President on the Form D that Nasus Pharma Ltd filed with the SEC on 25 February 2026, one of 8 people that filing names.
Udi Gilboa is named as Director on the Form D that Nasus Pharma Ltd filed with the SEC on 25 February 2026, one of 8 people that filing names.
On the filing as: Executive Officer, Director.
Dalia Megiddo is named as Chief Development Officer and Chief Medical Officer on the Form D that Nasus Pharma Ltd filed with the SEC on 25 February 2026, one of 8 people that filing names.
Ronnie Hershman is named as Director on the Form D that Nasus Pharma Ltd filed with the SEC on 25 February 2026, one of 8 people that filing names.
David Silberman is named as Director on the Form D that Nasus Pharma Ltd filed with the SEC on 25 February 2026, one of 8 people that filing names.
Sharon Shacham is named as Director on the Form D that Nasus Pharma Ltd filed with the SEC on 25 February 2026, one of 8 people that filing names.
Isaac Israel is named as Director on the Form D that Nasus Pharma Ltd filed with the SEC on 25 February 2026, one of 8 people that filing names.
8 people named on the filing — 3 holding an executive role and 5 as directors only.
Named as of the 2026-02-25 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Nasus Pharma Ltd
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Nasus Pharma Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Nasus Pharma Ltd covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Nasus Pharma LtdYou get an alert in MentionFox the next time this company shows up.
If you're behind Nasus Pharma Ltd: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Nasus Pharma Ltd. With no account yet, you sign up free and land on the result.
https://mentionfox.com/funding/nasus-pharma-ltd-form-d-26000001